Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
638
datasets available to search
ShareScore release 0.9.0
Dataset results
638 results for “Thrombosis”
A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart A
ClinicalTrials.gov study NCT02415400. IPD Sharing: Not stated. Countries: 37. Publications: 15.
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
ClinicalTrials.gov study NCT04498273. IPD Sharing: NO. Countries: 1. Publications: 5.
Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embo
ClinicalTrials.gov study NCT00439725. IPD Sharing: Not stated. Countries: 33. Publications: 6.
NASH Fitness Intervention in Thrombosis Trial (NASHFit)
ClinicalTrials.gov study NCT03518294. IPD Sharing: NO. Countries: 1. Publications: 2.
A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome
ClinicalTrials.gov study NCT00787332. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
ClinicalTrials.gov study NCT03080883. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients
ClinicalTrials.gov study NCT01784523. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)
ClinicalTrials.gov study NCT00443053. IPD Sharing: Not stated. Countries: 17. Publications: 2.
Data from: Trends in incidence and epidemiological characteristics of cerebral venous thrombosis in the United States
Objective To test the hypothesis that racial-, age- and sex-specific incidence of cerebral venous thrombosis (CVT) has increased in the United States over the last decade. Methods In this retrospective cohort study, validated International Classification of Disease codes were used to identify all new cases of CVT (n=5,567) in the State Inpatients Database (SID) of New York and Florida (2006-2016). A new CVT case was defined as first hospitalization for CVT in the SID without prior CVT hospitalization. CVT counts were combined with annual Census data to compute incidence. Joinpoint regression was used to evaluate trends in incidence over time. Results From 2006-2016, annual age and sex-standardized incidence of CVT in cases/million population ranged from 13.9-20.2, but incidence varied significantly by sex (females: 20.3-26.9; males 6.8-16.8) and by age/sex (females 18-44yo: 24.0-32.6%; males: 18-44yo: 5.3-12.8). Incidence also differed by race (Blacks:18.6-27.2; Whites: 14.3-18.5; Asians: 5.1-13.8). On joinpoint regression, incidence increased across 2006-2016 but most of this increase was driven by increase in all age groups of males (combined annualized percentage change (APC) 9.2%, p-value <0.001), females 45-64 yo (APC 7.8%, p-value <0.001) and females ≥65 yo (APC 7.4%, p-value <0.001). Incidence in females 18-44 yo remained unchanged over time. Conclusion: CVT incidence is disproportionately higher in blacks compared to other races. New CVT hospitalizations increased significantly over the last decade mainly in males and older females. Further studies are needed to determine whether this increase represents true increase from changing risk factors or artefactual increase from improved detection.
Data from: Numerical models for assessing the risk of leaflet thrombosis post-transcatheter aortic valve-in-valve implantation
<p>Leaflet thrombosis has been suggested as the reason for the reduced leaflet motion in cases of hypoattenuated leaflet thickening of bioprosthetic aortic valves. This work aimed to estimate the risk of leaflet thrombosis in two post-ViV configurations, using five different numerical approaches. Realistic ViV configurations were calculated by modeling the deployments of the latest version of transcatheter aortic valve devices (Medtronic Evolut PRO, Edwards SAPIEN 3) in the surgical Sorin Mitroflow. Computational fluid dynamics simulations of blood flow followed the dry models. Lagrangian and Eulerian measures of near-wall stagnation were implemented by particle and concentration tracking, respectively, to estimate the thrombogenicity and to predict the risk locations. Most of the numerical approaches indicate on a higher leaflet thrombosis risk in the Edwards SAPIEN 3 device because of its intra-annular implantation. The Eulerian approaches estimated high-risk locations in agreement with the WSS separation points. On the other hand, the Lagrangian approaches predicted high-risk locations at the proximal regions of the leaflets matching the low WSS magnitude regions of both TAVI models and reported clinical and experimental data. The proposed methods can help optimizing future designs of transcatheter aortic valves with minimal thrombotic risks.</p>
Direct oral anticoagulants in treatment of cerebral venous thrombosis: systematic review
Objectives Current guidelines do not recommend direct oral anticoagulants (DOAC) to treat cerebral venous thrombosis (CVT) despite their benefits over standard therapy. We performed a systematic review to summarize the published experience of DOAC therapy in CVT. Data sources MEDLINE, EMBASE, and COCHRANE databases up to November 18, 2020. Eligibility criteria All published articles of patients with CVT treated with DOAC were included. Studies without follow-up information were excluded. Data extraction and synthesis Two independent reviewers screened articles and extracted data. A risk of bias analysis was performed. Primary and secondary outcome measures Safety data included mortality, intracranial hemorrhage (ICH), or other adverse events. Efficacy data included recurrent CVT, recanalization rates, and disability by modified Rankin Scales (mRS). Results 33 studies met inclusion criteria. One randomized controlled trial, 5 observational cohorts, and 27 case series or studies reported 279 patients treated with DOAC for CVT: 41% dabigatran, 47% rivaroxaban, 10% apixaban, and 2% edoxaban, in addition to 315 patients treated with standard therapy. The observational cohorts showed a similar risk of death in DOAC and standard therapy arms (RR 2.12, 95%CI 0.29-15.59). New ICH was reported in 2 (0.7%) DOAC-treated patients and recurrent CVT occurred in 4 (1.5%). A favourable mRS between 0 and 2 was reported in 94% of DOAC-treated patients, more likely than standard therapy in observational cohorts (RR 1.13, 95% CI: 1.02-1.25). Conclusion The evidence for DOAC use in CVT is limited although suggests sufficient safety and efficacy despite variability in timing and dose of treatment. This systematic review highlights that further rigorous trials are needed to validate these findings and to determine optimal treatment regimens. PROSPERO ID: CRD42017078398
Uncertainty quantification of a thrombosis model considering the clotting assay PFA-100Ⓡ
<p>Scripts and datasets that were used to obtain figures 4B, 6, 7, 8, 9, 10, and 11.</p>
Prenylcysteine Oxidase 1 (PCYOX1), a New Player in Thrombosis
<p>This record contains raw data related to the article "Prenylcysteine Oxidase 1 (PCYOX1), a New Player in Thrombosis"</p> <p>Abstract: Prenylcysteine Oxidase 1 (PCYOX1) is an enzyme involved in the degradation of prenylated<br> proteins. It is expressed in different tissues including vascular and blood cells. We recently<br> showed that the secretome from Pcyox1-silenced cells reduced platelet adhesion both to fibrinogen<br> and endothelial cells, suggesting a potential contribution of PCYOX1 into thrombus formation. Here,<br> we show that in vivo thrombus formation after FeCl3 injury of the carotid artery was delayed in<br> Pcyox1/ mice, which were also protected from collagen/epinephrine induced thromboembolism.<br> The Pcyox1/ mice displayed normal blood cells count, vascular procoagulant activity and plasma<br> fibrinogen levels. Deletion of Pcyox1 reduced the platelet/leukocyte aggregates in whole blood, as<br> well as the platelet aggregation, the alpha granules release, and the IIb3 integrin activation in<br> platelet-rich plasma, in response to adenosine diphosphate (ADP) or thrombin receptor agonist peptide<br> (TRAP).Washed platelets from the Pcyox1/ and WT animals showed similar phosphorylation<br> pathway activation, adhesion ability and aggregation. The presence of Pcyox1/ plasma impaired<br> agonist-induced WT platelet aggregation. Our findings show that the absence of PCYOX1 results<br> in platelet hypo-reactivity and impaired arterial thrombosis, and indicates that PCYOX1 could be a<br> novel target for antithrombotic drugs.</p>
Analysis of the effectiveness and safety of conventional anticoagulants in preventing deep vein thrombosis after total knee arthroplasty in patients undergoing total knee arthroplasty at high altitudes
<p><strong><span>Analysis of the effectiveness and safety of conventional anticoagulants in preventing deep vein thrombosis after total knee arthroplasty in patients undergoing total knee arthroplasty at high altitudes</span></strong></p>
Xylitol is associated with cardiovascular event risks and enhances platelet responsiveness and thrombosis potential in vivo
Open the record for dataset details and reuse information.
Immature Granulocytes As Biomarker In Peripheral Blood For Sub-acute Inflammation In Early Diagnosis of Lower Extremity Arterial Thrombosis
<p>Early diagnosis and treatment are critically important in terms of prognosis in subacute arterial thrombosis. The aim of our study is to investigate whether immature granulocytes are useful in the early diagnosis of subacute artery thrombosis. This retrospective study was conducted in a single center between 2019 and 2021 A total of 99 patients with lower extremity chronic peripheral arterial disease were included in the study. Among these patients, 27 patients with subacute artery thrombosis were included in SAT group. The remaining 72 patients were included in control group. The blood samples of the patients in both groups, belonging to the first application and before receiving any treatment, were analyzed. CBC parameters calculated with automatic hematological analyzer between groups were compared statistically. Our study showed that immature granulocytes can be very useful in the diagnosis of SAT, with a sensitivity of 81% and a specificity of 90%.</p>
Aspirin® Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With PTS
ClinicalTrials.gov study NCT04128956. IPD Sharing: NO. Countries: 3. Publications: 1.
Assessment of Long-Term Out-of-Hospital Treatment of Patients With Proximal Deep Vein Thrombosis (DVT) Using Low-Molecular-Weight Heparin (LMWH) Versus LMWH Followed by Warfarin
ClinicalTrials.gov study NCT00203658. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study)
ClinicalTrials.gov study NCT00203580. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Single Complete Compression Ultrasonography to Rule Out Deep Vein Thrombosis During Pregnancy and Postpartum
ClinicalTrials.gov study NCT00740454. IPD Sharing: Not stated. Countries: 2. Publications: 5.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.